Integra LifeSciences prices $450 million senior secured notes

Integra LifeSciences Holdings Corporation (NASDAQ: IART) has finalized the pricing for a $450,000,000 aggregate principal amount of 9.500% senior secured notes due 2033. The company announced the terms on October 9, 2026, in Princeton, N.J., signaling the next phase of a broader refinancing strategy that aims to restructure its existing debt load.

The new notes will serve as general senior secured obligations of the company, backed by guarantees from wholly-owned domestic subsidiaries that act as guarantors under Integra's current senior secured credit facilities. This structure ensures the debt is secured by the same corporate entities that support its existing borrowing arrangements. The sale of these instruments is expected to close on or about October 19, 2026, subject to customary closing conditions.

Integra intends to use the net proceeds from this offering, combined with borrowings under a new credit facility, to refinance its existing credit facilities and cover associated fees and expenses. The transaction is part of a comprehensive refinancing effort designed to update the company's capital structure. By consolidating its obligations, Integra is positioning its balance sheet for the next decade, with the notes maturing in 2033.

The offering is being conducted as a private placement. The notes and related guarantees have not been registered under the Securities Act of 1933 or applicable state securities laws. They were offered only to persons reasonably believed to be qualified institutional buyers under Rule 144A of the Securities Act and to certain non-U.S. persons outside the United States in compliance with Regulation S. This release was issued pursuant to Rule 135c and does not constitute an offer to sell or a solicitation of an offer to buy any securities.

Integra LifeSciences operates as a global medical technology company focused on neurosurgery and tissue reconstruction. The company states that its portfolio of technologies is designed to deliver impactful care in specialized fields requiring high precision. Chris Ward serves as the investor relations contact, while Laurene Isip handles media inquiries.

The company notes that the release contains forward-looking statements involving risks and uncertainties. These statements reflect management's judgment as of the announcement date and may differ materially from actual results due to various factors, including market conditions and the successful consummation of the offering. Integra undertakes no obligation to update these statements except as required by law.